Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Madan Uprety

Psychiatry Reston, VA Medical Doctor

NPI 1528109758 CMS profile 295843

12359 Sunrise Valley Dr Ste 320, Reston, VA 20191

Open in the dashboard

General payments

$2,730

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madan Uprety of Reston, VA is reported in the CMS Open Payments database as having received $2,730 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $324 9
2024 General $254 8
2023 General $652 22
2022 General $385 16
2021 General $526 28
2020 General $75 4
2019 General $515 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madan Uprety
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Madan Uprety were reported at $324. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Madan Uprety Psychiatry median Middle half National median
2019 $515 $184 $59–$605 $163
2020 $75 $119 $36–$372 $114
2021 $526 $143 $43–$576 $132
2022 $385 $153 $50–$590 $149
2023 $652 $170 $56–$651 $160
2024 $254 $179 $57–$673 $164
2025 $324 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $603 12 payments
  2. Lundbeck LLC $347 15 payments
  3. Otsuka America Pharmaceutical, Inc. $246 18 payments
  4. Supernus Pharmaceuticals, Inc. $241 10 payments
  5. Idorsia Pharmaceuticals US Inc $177 5 payments
  6. Sunovion Pharmaceuticals Inc. $143 14 payments
  7. AbbVie, Inc. $122 6 payments
  8. Jazz Pharmaceuticals Inc. $118 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $109 5 payments
  10. Allergan Inc. $106 5 payments
  11. Other $517 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,730 124 payments
Products named General payments · program years 2019–2025
  1. SPRAVATO $559 10 payments
  2. QELBREE $241 10 payments
  3. BRINTELLIX $202 9 payments
  4. REXULTI Psychiatry $177 11 payments
  5. QUVIVIQ $177 5 payments
  6. REXULTI Psychiatry $145 6 payments
  7. LATUDA $143 14 payments
  8. VRAYLAR Neuroscience $123 6 payments
  9. INVEGA SUSTENNA $112 5 payments
  10. VRAYLAR Neuroscience $105 5 payments
  11. Other $1,143 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record